Metástasis

InvestorBrandNetwork Announces Gamechangers LIVE Interview with CNS Pharmaceuticals Inc. Chairman & CEO John Climaco

Retrieved on: 
Wednesday, December 9, 2020
Branches of biology, Oncology, Central nervous system, Neuroscience, Cancer, Metástasis

The broadcast, hosted by Executive Coach and Speaker Sergio Tigera, is available for on-demand viewing on Gamechangers LIVE .

Key Points: 
  • The broadcast, hosted by Executive Coach and Speaker Sergio Tigera, is available for on-demand viewing on Gamechangers LIVE .
  • During the interview, Climaco provided an overview of CNS Pharmaceuticals and its lead drug candidate, Berubicin .
  • I have done all kinds of different things in my career, been in the health care industry for a long time.
  • CNS Pharmaceuticals is developing novel treatments for primary and metastatic cancers of the brain and central nervous system.

Delcath Systems Announces Pricing of Public Offering of Common Stock

Retrieved on: 
Wednesday, December 9, 2020
Medical specialties, Medicine, Clinical medicine, Delcath Systems, Canaccord Genuity, Genuity, Interventional oncology, Metástasis, Oncology

NEW YORK, Dec. 09, 2020 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH ), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, today announced the pricing of an underwritten public offering of 1,460,027 shares of its common stock at a public offering price of $13.25 per share.

Key Points: 
  • NEW YORK, Dec. 09, 2020 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH ), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, today announced the pricing of an underwritten public offering of 1,460,027 shares of its common stock at a public offering price of $13.25 per share.
  • The gross proceeds of the offering to the Company are expected to be approximately $19.3 million, before deducting the underwriting discounts and commissions and other estimated offering expenses.
  • Canaccord Genuity and Roth Capital Partners are acting as joint book-running managers for the proposed offering.
  • Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers.

#ThisIsMBC Perseverance Campaign from Eisai and METAvivor Captures the Joys, Difficulties and Realities Faced by People Living with Metastatic Breast Cancer

Retrieved on: 
Tuesday, December 8, 2020
Cancer, Metastatic breast cancer, MBC, Breast cancer, Metástasis, Medical specialties, Health

Perseverance showcases imagery of a diverse group of 12 participants capturing the daily joy, difficulty and reality of living under pressure with MBC.

Key Points: 
  • Perseverance showcases imagery of a diverse group of 12 participants capturing the daily joy, difficulty and reality of living under pressure with MBC.
  • To learn more about #ThisIsMBC and this initiative and find helpful resources on metastatic breast cancer, please visit METAvivor.org or MBCInfoCenter.com .
  • METAvivor Research and Support Inc. is an Annapolis-based, 501(c)(3), volunteer-led, non-profit organization founded by metastatic breast cancer (MBC) patients in 2009.
  • METAvivor has gained a rapidly growing following within the breast cancer community, and has become a leader in its field.

DGAP-News: Data published in Cancer Research show Secarna Pharmaceuticals' LNAplus(TM) ASOs targeting metadherin significantly slow progression and metastasis of colorectal and lung cancers in vivo

Retrieved on: 
Tuesday, December 8, 2020
Branches of biology, Oncology, MTDH, Metástasis, Health, Cancer, Brachyury, Lung cancer, Medical specialties, Tumor microenvironment, ARHGDIB, Secarna's proprietary drug discovery platform, LNAplusTM, Secarna Pharmaceuticals GmbH & Co. KG

The article, "Therapeutic Targeting of Metadherin Suppresses Colorectal and Lung Cancer Progression and Metastasis," is available here: https://cancerres.aacrjournals.org/content/early/2020/11/25/0008-5472.CA... .

Key Points: 
  • The article, "Therapeutic Targeting of Metadherin Suppresses Colorectal and Lung Cancer Progression and Metastasis," is available here: https://cancerres.aacrjournals.org/content/early/2020/11/25/0008-5472.CA... .
  • In lung cancer, MTDH was shown to promote tumor progression by suppressing T cell infiltration into the tumor.
  • In mouse tumor models, the ASOs were shown to significantly inhibit tumor progression and metastasis in colorectal, lung and also breast cancer.
  • Jonas Renz, Managing Director and Co-founder of Secarna Pharmaceuticals, said: "These published data provide compelling new insights into the mechanism of metadherin in promoting lung and colorectal cancers.

Kevin Muir Joins Delcath Systems, Inc. as VP, Commercial Operations

Retrieved on: 
Monday, December 7, 2020
Medical specialties, Oncology, Medicine, Clinical medicine, Delcath Systems, Metástasis, Interventional oncology, Liver

NEW YORK, Dec. 07, 2020 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced Kevin Muir has joined the company as Vice President of Commercial Operations.

Key Points: 
  • NEW YORK, Dec. 07, 2020 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced Kevin Muir has joined the company as Vice President of Commercial Operations.
  • Gerard Michel, CEO of Delcath, commented, We are thrilled that Kevin is joining the Delcath team as VP of Commercial Operations.
  • His hire is another important step in Delcaths transition from a development to commercial stage company.
  • Mr. Muir joins Delcath Systems with 20 years of sales and marketing experience in the biotherapeutics and medical technology industries.

Sermonix to Present Poster on Patient Awareness of ESR1 Mutation Biomarker Testing, Attitudes on Metastatic Breast Cancer Quality of Life at Virtual San Antonio Breast Cancer Symposium 2020

Retrieved on: 
Wednesday, December 2, 2020
Breast cancer, Health, Metastatic breast cancer, Cancer, Metástasis, Clinical medicine, Breast cancer management, Triple-negative breast cancer

ESR1 mutations occur in up to 40% of women with metastatic breast cancer and may confer a worse prognosis and poor response to currently available endocrine treatments1.

Key Points: 
  • ESR1 mutations occur in up to 40% of women with metastatic breast cancer and may confer a worse prognosis and poor response to currently available endocrine treatments1.
  • As a womens oncology company, we embrace the significance of the metastatic breast cancer patient voice, said Dr. Miriam Portman.
  • Treatment options for metastatic breast cancer patients with an ESR1 mutation are limited and currently there are no approved therapies specifically for these women.
  • The survey also looked to establish which quality-of-life concerns are the most prevalent among metastatic breast cancer patients.

Iovance Biotherapeutics to Present at Upcoming Conferences in December

Retrieved on: 
Monday, November 30, 2020
Clinical medicine, Medicine, Medical specialties, Oncology, Lymphocytes, Tumor-infiltrating lymphocytes, Melanoma, Iovance Biotherapeutics, Cancer, Metástasis, Cancer immunotherapy, Adoptive cell transfer

Tumor infiltrating lymphocyte (TIL) therapy uses a patients own immune cells to attack cancer.

Key Points: 
  • Tumor infiltrating lymphocyte (TIL) therapy uses a patients own immune cells to attack cancer.
  • TIL cells are extracted from a patients own tumor tissue, expanded through a proprietary process, and infused back into the patient.
  • The company has completed dosing in the pivotal study in patients with metastatic melanoma and cervical cancer.
  • A clinical study to investigate Iovance T cell therapy for blood cancers called peripheral blood lymphocyte (PBL) therapy is open to enrollment.

Q BioMed's Strontium89 Advertisement "Unfinished Business" Selected for Prestigious Ads of the World's Best Creative Campaigns

Retrieved on: 
Friday, November 20, 2020
Musculoskeletal system, Physical sciences, Anatomy, Strontium-89, Bone metastasis, Bone, Strontium, Radiation therapy, Metástasis, Metastatic breast cancer

Strontium89, the radiotherapy with nearly 30 years of proven results in relieving painful bone metastases, is available in the US from Q BioMed.

Key Points: 
  • Strontium89, the radiotherapy with nearly 30 years of proven results in relieving painful bone metastases, is available in the US from Q BioMed.
  • "Q BioMed is committed to making Strontium89, an effective treatment for pain resulting from bone metastases, widely available again.
  • Bone marrow toxicity is to be expected following the administration of Strontium-89 Chloride Injection, particularly white blood cells and platelets.
  • Because Strontium-89 Chloride Injection acts as a calcium analog, secretion of Strontium-89 Chloride Injection into human milk is likely.

Q BioMed's Strontium89 Advertisement "Unfinished Business" Selected for Prestigious Ads of the World's Best Creative Campaigns

Retrieved on: 
Friday, November 20, 2020
Musculoskeletal system, Physical sciences, Anatomy, Strontium-89, Bone metastasis, Bone, Strontium, Radiation therapy, Metástasis, Metastatic breast cancer

Strontium89, the radiotherapy with nearly 30 years of proven results in relieving painful bone metastases, is available in the US from Q BioMed.

Key Points: 
  • Strontium89, the radiotherapy with nearly 30 years of proven results in relieving painful bone metastases, is available in the US from Q BioMed.
  • "Q BioMed is committed to making Strontium89, an effective treatment for pain resulting from bone metastases, widely available again.
  • Bone marrow toxicity is to be expected following the administration of Strontium-89 Chloride Injection, particularly white blood cells and platelets.
  • Because Strontium-89 Chloride Injection acts as a calcium analog, secretion of Strontium-89 Chloride Injection into human milk is likely.

Study Shows Biocept's Assays are Viable and Sensitive for Detecting Tumor Cells and Biomarkers in the Cerebrospinal Fluid of Patients with Breast and Lung Cancer that has Metastasized to the Central Nervous System

Retrieved on: 
Friday, November 20, 2020
Clinical medicine, Medicine, Medical specialties, Oncology, Anatomical pathology, Medical signs, DNA, Circulating tumor DNA, Neoplasms, Cancer, Metástasis, Molecular diagnostics

CSF cytology has limited sensitivity and provides no additional information needed for target therapy choice.

Key Points: 
  • CSF cytology has limited sensitivity and provides no additional information needed for target therapy choice.
  • "Once a tumor has metastasized to the brain, CTCs and circulating tumor DNA (ctDNA) can be found in the cerebrospinal fluid," said Dr. Kesari.
  • This study highlights the potential of CSF-based diagnostics for longitudinal monitoring cancers in the central nervous system."
  • Biocept, Inc.is a molecular diagnostics company with commercialized assays for lung, breast, gastric, colorectal and prostate cancers, and melanoma.